CERT - Certara, Inc. Stock Price, Fair Value and News

16.46USD+0.11 (+0.67%)Delayed as of 09 May 2024, 09:50 am ET

Market Summary

USD16.46+0.11

Delayedas of 09 May 2024, 09:50 am

0.67%

CERT Alerts

1 major insider sales recently.

Big fall in earnings (Y/Y)
Losses in recent quarter

CERT Stock Price

View Fullscreen

CERT RSI Chart

CERT Valuation

Market Cap

2.6B

Price/Earnings (Trailing)

-42.83

Price/Sales (Trailing)

7.29

EV/EBITDA

-70.34

Price/Free Cashflow

35.06

CERT Price/Sales (Trailing)

CERT Profitability

Operating Margin

60.90%

EBT Margin

-17.48%

Return on Equity

-5.82%

Return on Assets

-3.98%

Free Cashflow Yield

2.85%

CERT Fundamentals

CERT Revenue

Revenue (TTM)

360.7M

Rev. Growth (Yr)

7.04%

Rev. Growth (Qtr)

9.82%

CERT Earnings

Earnings (TTM)

-61.4M

Earnings Growth (Yr)

-444.85%

Earnings Growth (Qtr)

62.4%

Breaking Down CERT Revenue

52 Week Range

13.7822.65

(Low)(High)

Last 7 days

-5.4%

Last 30 days

-13.6%

Last 90 days

-2.9%

Trailing 12 Months

-21.7%

How does CERT drawdown profile look like?

CERT Financial Health

Current Ratio

3.26

Debt/Equity

0.27

Debt/Cashflow

0.27

CERT Investor Care

Shares Dilution (1Y)

0.63%

Diluted EPS (TTM)

-0.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	360.7M	0	0	0
2023	344.4M	352.1M	353.0M	354.3M
2022	300.9M	313.6M	324.4M	335.6M
2021	252.8M	261.8M	275.4M	286.1M
2020	217.3M	226.0M	234.8M	243.5M
2019	0	0	0	208.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Certara, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	smith patrick f	sold	-243,161	16.8546	-14,427	president, drug dev solutions
Apr 01, 2024	feehery william f	sold (taxes)	-762,206	17.88	-42,629	chief executive officer
Apr 01, 2024	feehery william f	acquired	-	-	69,799	chief executive officer
Apr 01, 2024	aspbury robert	acquired	-	-	16,498	president; scientific software
Apr 01, 2024	gallagher john e	sold (taxes)	-162,297	17.88	-9,077	chief financial officer
Apr 01, 2024	traynor richard m.	acquired	-	-	13,295	svp and general counsel
Apr 01, 2024	sherman nicolette d	sold (taxes)	-46,094	17.88	-2,578	chief human resources officer
Apr 01, 2024	pedersen leif e	sold (taxes)	-106,404	17.88	-5,951	president, chief commercal off
Apr 01, 2024	smith patrick f	sold (taxes)	-124,355	17.88	-6,955	president, drug dev solutions
Apr 01, 2024	aspbury robert	sold (taxes)	-189,975	17.88	-10,625	president; scientific software

Which funds bought or sold CERT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	M&T Bank Corp	reduced	-1.77	-3,236	2,371,880	0.01%
May 07, 2024	OPPENHEIMER ASSET MANAGEMENT INC.	reduced	-1.57	1,388	2,427,100	0.04%
May 07, 2024	NorthRock Partners, LLC	sold off	-100	-203,481	-	-%
May 07, 2024	Arizona State Retirement System	reduced	-1.65	-159	549,810	-%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	reduced	-8.36	-33,032	449,092	-%
May 07, 2024	Washington Trust Advisors, Inc.	unchanged	-	78.00	4,757	-%
May 07, 2024	Swiss National Bank	unchanged	-	63,916	3,940,750	-%
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-16.34	-631,000	3,588,000	-%
May 07, 2024	TimesSquare Capital Management, LLC	added	2.2	348,000	9,305,000	0.14%
May 07, 2024	SEI INVESTMENTS CO	added	12.41	1,597,290	12,793,400	0.02%

Are Funds Buying or Selling CERT?

Are funds buying CERT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CERT

No. of Funds

Unveiling Certara, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	7.85%	12,544,560	SC 13G/A
Jan 30, 2024	baillie gifford & co	5.58%	8,921,463	SC 13G/A
Jan 25, 2024	blackrock inc.	8.7%	13,956,611	SC 13G
Feb 09, 2023	vanguard group inc	6.80%	10,850,994	SC 13G/A
Feb 09, 2023	eqt avatar parent l.p.	0%	0	SC 13G/A
Jan 18, 2023	baillie gifford & co	6.40%	10,223,809	SC 13G/A
Dec 16, 2022	arsenal capital partners iii lp	2.2%	3,559,745	SC 13D
Feb 14, 2022	eqt avatar parent l.p.	23.5%	37,458,939	SC 13G/A
Feb 09, 2022	vanguard group inc	5.92%	9,310,068	SC 13G

Recent SEC filings of Certara, Inc.

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 12, 2024	DEFA14A	DEFA14A
Apr 10, 2024	ARS	ARS
Apr 10, 2024	DEF 14A	DEF 14A
Apr 10, 2024	DEFA14A	DEFA14A
Apr 05, 2024	4/A	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading

Peers (Alternatives to Certara, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	463.9B	371.6B	10.35%	2.61%	20.73	1.25	14.64%	11.24%
CI	98.7B	206.0B	-2.97%	32.18%	25.6	0.48	12.55%	-43.95%
HCA	81.0B	66.7B	-5.69%	12.88%	14.81	1.21	9.59%	-4.59%
CVS	68.9B	360.9B	-26.25%	-21.54%	9.41	0.19	9.07%	78.49%
CNC	40.5B	155.5B	3.95%	12.19%	14.8	0.26	6.34%	84.42%
DVA	11.9B	12.3B	1.61%	34.91%	14.61	0.97	5.77%	58.74%
UHS	11.4B	14.7B	-1.27%	18.38%	13.95	0.78	7.99%	19.23%
MID-CAP
CHE	8.7B	2.3B	-8.25%	4.64%	30.56	3.78	5.96%	18.29%
ACHC	6.1B	3.0B	-12.48%	-3.87%	-542.41	2.05	10.92%	-104.06%
AMN	2.3B	3.8B	2.67%	-35.23%	10.84	0.6	-27.73%	-52.50%
AMEH	2.1B	1.4B	-9.72%	19.70%	34.78	1.52	21.19%	34.42%
SMALL-CAP
ADUS	1.8B	1.1B	5.80%	29.14%	26.7	1.61	11.45%	30.74%
BKD	1.4B	3.0B	1.30%	77.47%	-7.76	0.44	4.98%	4.88%
BEAT	55.0M	-	-4.65%	-8.89%	-3.76	-	-	-12.94%
AMS	19.3M	21.3M	3.37%	9.25%	36.22	0.91	8.00%	-62.25%

Certara, Inc. News

Latest updates

Certara, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	9.8%	97.00	88.00	86.00	90.00	90.00	87.00	85.00	83.00	82.00	75.00	74.00	70.00	67.00	65.00	60.00	61.00	57.00	-
Cost Of Revenue	-100.0%	-	34.00	36.00	36.00	35.00	32.00	33.00	35.00	33.00	29.00	29.00	28.00	26.00	35.00	23.00	21.00	22.00	-
Operating Expenses	-6.0%	59.00	62.00	102	41.00	48.00	43.00	41.00	43.00	43.00	43.00	46.00	37.00	35.00	83.00	30.00	27.00	27.00	-
S&GA Expenses	23.2%	11.00	9.00	7.00	8.00	8.00	8.00	6.00	7.00	6.00	7.00	5.00	5.00	4.00	10.00	3.00	3.00	3.00	-
R&D Expenses	49.6%	12.00	8.00	9.00	8.00	9.00	7.00	6.00	8.00	8.00	7.00	5.00	5.00	5.00	11.00	3.00	3.00	3.00	-
EBITDA Margin	-22.6%	-0.11*	-0.09*	-0.04*	0.13*	0.11*	0.11*	0.10*	0.06*	0.06*	0.05*	-0.15*	-0.13*	-	-	-	-	-	-
Interest Expenses	-2.0%	6.00	6.00	6.00	6.00	5.00	5.00	5.00	4.00	3.00	3.00	3.00	6.00	4.00	5.00	6.00	7.00	7.00	-
Income Taxes	-1143.1%	-0.75	0.00	-4.64	4.00	1.00	-5.45	5.00	3.00	2.00	10.00	-1.63	1.00	1.00	-5.48	0.00	4.00	1.00	-
Earnings Before Taxes	56.1%	-5.43	-12.38	-53.61	8.00	2.00	4.00	8.00	3.00	4.00	-0.16	-3.39	-1.40	2.00	-59.93	2.00	7.00	2.00	-
EBT Margin	-12.3%	-0.17*	-0.16*	-0.11*	0.07*	0.05*	0.06*	0.05*	0.01*	0.00*	-0.01*	-0.23*	-0.22*	-	-	-	-	-	-
Net Income	62.4%	-4.68	-12.46	-48.96	5.00	1.00	9.00	4.00	-0.59	2.00	-9.70	-1.76	-2.86	1.00	-54.45	1.00	3.00	1.00	-
Net Income Margin	-9.0%	-0.17*	-0.16*	-0.10*	0.05*	0.04*	0.04*	-0.01*	-0.03*	-0.04*	-0.05*	-0.21*	-0.21*	-	-	-	-	-	-
Free Cashflow	-83.6%	4.00	22.00	31.00	18.00	10.00	35.00	24.00	23.00	9.00	21.00	20.00	14.00	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-1.3%	1,542	1,563	1,527	1,572	1,567	1,573	1,509	1,502	1,507	1,512	1,415	1,265	1,263	1,269
Current Assets	-3.5%	328	340	370	353	348	342	305	286	275	275	505	345	348	347
Cash Equivalents	-4.3%	225	235	272	245	244	237	214	198	185	187	418	270	273	273
Net PPE	6.6%	3.00	3.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00	4.00
Goodwill	-0.1%	716	716	25.00	2.00	719	718	697	701	705	703	181	524	519	519
Liabilities	-5.5%	488	516	475	475	482	493	454	453	459	470	443	431	435	447
Current Liabilities	-22.6%	101	130	105	103	94.00	103	77.00	82.00	82.00	92.00	70.00	59.00	63.00	75.00
Long Term Debt	-0.2%	288	288	289	289	290	290	290	291	291	292	292	293	294	294
LT Debt, Current	0%	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	5.00	5.00
LT Debt, Non Current	-100.0%	-	288	289	289	290	290	290	291	291	292	292	293	294	294
Shareholder's Equity	0.7%	1,054	1,047	1,052	1,097	1,085	1,080	1,054	1,048	1,048	1,042	971	835	827	822
Retained Earnings	-4.0%	-120	-116	-103	-54.81	-59.51	-60.87	-70.05	-73.98	-73.39	-75.60	-65.90	-64.14	-61.29	-62.34
Additional Paid-In Capital	1.1%	1,191	1,178	1,171	1,162	1,159	1,150	1,144	1,137	1,127	1,120	1,039	897	890	885
Shares Outstanding	0.2%	160	160	160	160	160	160	157	156	156	150	149	147	-	-
Float	-	-	-	-	2,200	-	-	-	2,500	-	-	-	2,100	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-81.6%	4,296	23,326	31,414	18,058	9,957	35,485	23,996	23,259	9,803	20,831	20,001	14,622	4,934	12,681	15,488	7,818	8,823	-
Cashflow From Investing	94.1%	-3,578	-61,047	-4,041	-11,731	-2,731	-12,599	-3,324	-3,238	-8,676	-249,323	-2,600	-14,541	-3,458	-1,403	-1,968	-2,232	-3,009	-
Cashflow From Financing	-726.4%	-10,347	-1,252	-925	-6,420	-850	-968	-1,344	-3,531	-1,520	-3,644	132,200	-4,310	-855	232,317	-41,289	-1,845	19,031	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,024	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CERT Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 96,654	$ 90,301
Cost of revenues	39,255	34,856
Operating expenses:
Sales and marketing	10,687	8,002
Research and development	11,995	9,287
General and administrative	22,979	19,772
Intangible asset amortization	12,593	10,535
Depreciation and amortization expense	432	411
Total operating expenses	58,686	48,007
Income (loss) from operations	(1,287)	7,438
Other income (expenses):
Interest expense	(5,751)	(5,475)
Net other income	1,604	506
Total other expenses	(4,147)	(4,969)
Income (loss) before income taxes	(5,434)	2,469
Provision (benefit) for income taxes	(751)	1,111
Net income (loss)	(4,683)	1,358
Other comprehensive income (loss):
Foreign currency translation adjustment, net of tax of $60, $(182), respectively	(7)	2,601
Change in fair value from interest rate swap, net of tax of $186, $(588), respectively	564	(1,691)
Total other comprehensive income	557	910
Comprehensive income (loss)	$ (4,126)	$ 2,268
Net income (loss) per share attributable to common stockholders:
Basic (in dollar per share)	$ (0.03)	$ 0.01
Diluted (in dollar per share)	$ (0.03)	$ 0.01
Weighted average common shares outstanding:
Basic (in shares)	159,524,270	158,177,025
Diluted (in shares)	159,524,270	159,727,412

CERT Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 224,776	$ 234,951
Accounts receivable, net of allowance for credit losses of $1,341 and $1,312, respectively	80,949	84,857
Prepaid expenses and other current assets	22,732	20,393
Total current assets	328,457	340,201
Other assets:
Property and equipment, net	2,846	2,670
Operating lease right-of-use assets	14,292	9,604
Goodwill	715,620	716,333
Intangible assets, net of accumulated amortization of $289,090 and $273,522, respectively	473,687	487,043
Deferred income taxes	4,236	4,236
Other long-term assets	3,240	3,053
Total assets	1,542,378	1,563,140
Current liabilities:
Accounts payable	3,733	5,171
Accrued expenses	32,744	56,779
Current portion of deferred revenue	56,801	60,678
Current portion of long-term debt	3,020	3,020
Other current liabilities	4,331	4,375
Total current liabilities	100,629	130,023
Long-term liabilities:
Deferred revenue, net of current portion	1,437	1,070
Deferred income taxes	46,307	50,826
Operating lease liabilities, net of current portion	11,631	6,955
Long-term debt, net of current portion and debt discount	287,772	288,217
Other long-term liabilities	40,244	39,209
Total liabilities	488,020	516,300
Commitments and contingencies
Stockholders' equity
Preferred shares, $0.01 par value, 50,000,000 shares authorized, no shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	0	0
Common shares, $0.01 par value, 600,000,000 shares authorized, 160,687,886 and 160,284,901 shares issued as of March 31, 2024 and December 31, 2023, respectively; 160,191,094 and 159,848,286 shares outstanding as of March 31, 2024 and December 31, 2023, respectively	1,607	1,603
Additional paid-in capital	1,191,237	1,178,461
Accumulated deficit	(120,913)	(116,230)
Accumulated other comprehensive loss	(7,036)	(7,593)
Treasury stock at cost, 496,792 and 436,615 shares at March 31, 2024 and December 31, 2023, respectively	(10,537)	(9,401)
Total stockholders' equity	1,054,358	1,046,840
Total liabilities and stockholders' equity	$ 1,542,378	$ 1,563,140

About Certara, Inc.

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, the Netherlands, the Philippines, Poland, Portugal, Spain, Switzerland, and the United Kingdom. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

CEO	Dr. William F. Feehery Ph.D.
WEBSITE	certara.com
INDUSTRY	Healthcare Plans
EMPLOYEES	1150

Certara, Inc. Frequently Asked Questions

What is the ticker symbol for Certara, Inc.? What does CERT stand for in stocks?

CERT is the stock ticker symbol of Certara, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Certara, Inc. (CERT)?

As of Wed May 08 2024, market cap of Certara, Inc. is 2.63 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CERT stock?

You can check CERT's fair value in chart for subscribers.

What is the fair value of CERT stock?

You can check CERT's fair value in chart for subscribers. The fair value of Certara, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Certara, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CERT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Certara, Inc. a good stock to buy?

The fair value guage provides a quick view whether CERT is over valued or under valued. Whether Certara, Inc. is cheap or expensive depends on the assumptions which impact Certara, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CERT.

What is Certara, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, CERT's PE ratio (Price to Earnings) is -42.83 and Price to Sales (PS) ratio is 7.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CERT PE ratio will change depending on the future growth rate expectations of investors.